cAMP signaling is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
åœ¨ä¸´åºŠç ”ç©¶ä¹‹å¤–ï¼Œç‰¹æ²™èŽ«ç‘žæž—å¸¸è¢«è®¨è®ºä¸ºç”Ÿé•¿æ¿€ç´ åˆ†æ³Œä¿ƒè¿›å‰‚ï¼Œä½†è¿™ä¸€è¯´æ³•éœ€è¦é™å®šã€‚它并ä¸ç‰åŒäºŽç”Ÿé•¿æ¿€ç´ 本身，也ä¸å±žäºŽæ™®é€šå‡é‡è¯ç‰©ã€‚éƒ¨åˆ†ç ”ç©¶å…³æ³¨å…¶å‡å°‘腹部脂肪和改善脂质谱的潜力，å¦ä¸€äº›ç ”ç©¶åˆ™å…³æ³¨èƒ°å²›ç´ æŠµæŠ—å’Œ IGF-1 å‡é«˜ç‰ä¿¡å·ã€‚这些效应的临床æ„义ä»åœ¨è¯„ä¼°ä¸ï¼Œå°šæœªå½¢æˆç»Ÿä¸€ç»“论。
特沙莫瑞林是一ç§åˆæˆè‚½ï¼Œå…¶åºåˆ—ä¸Žäººç”Ÿé•¿æ¿€ç´ é‡Šæ”¾æ¿€ç´ çš„ 44 个氨基酸形å¼ç›¸å…³ã€‚它在 N 端带有åå¼-3-己烯酰基修饰，这一改动å¯å‡ç¼“二肽基肽酶 IV çš„é™è§£ã€‚该化åˆç‰©å±žäºŽç”Ÿé•¿æ¿€ç´ é‡Šæ”¾æ¿€ç´ å—体激动剂，å¯åˆºæ¿€åž‚ä½“é‡Šæ”¾ç”Ÿé•¿æ¿€ç´ ã€‚ç ”ç©¶æ–‡çŒ®é€šå¸¸å°†å…¶å½’å…¥åˆæˆè‚½ç±»è¯ç‰©ï¼Œè€Œéžå°åˆ†å化åˆç‰©ã€‚
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
| Property | Value | Notes |
|---|---|---|
| 分å类型 | åˆæˆè‚½ | å« 44 个氨基酸残基的 GHRH 类似物 |
| N 端修饰 | åå¼-3-己烯酰基 | 用于抵抗二肽基肽酶 IV é™è§£ |
| 首次批准 | 2010 年，美国 | 用于 HIV 相关脂肪è¥å…»ä¸è‰¯ |
| 作用é¶ç‚¹ | ç”Ÿé•¿æ¿€ç´ é‡Šæ”¾æ¿€ç´ å—体 | ä½äºŽåž‚体å‰å¶ |
| 主è¦ç ”究终点 | 内è„脂肪å˜åŒ– | éžæ€»ä½“é‡æˆ–ç˜¦ä½“é‡ |
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Drugs in the US were largely unregulated until the early 20th century. Opium had been used to relieve pain since the Revolutionary War, but the use of opiates in the civilian population began to increase dramatically in the late 1800s, and cocaine use became prevalent. Alcohol consumption steadily grew, as did the temperance movement, well-supported by the middle class, promoting moderation or abstinence. The practice of smoking cannabis began to be noticed in the early 1900s. State and local governments began enacting drug laws in the mid-1800s. Under the US Constitution, the authority to control dangerous drugs exists separately at both the federal and state level. Federal drug legislation arrived after the turn of the century.
To avoid this, freshly prepared samples as well as complementary analysis methods are used for confident nuclear materials characterization. The decay of nuclear samples makes rapid analysis methods highly desirable.
== Interactions == Lenvatinib inhibits the liver enzyme CYP3A, which also happens to be a metabolic enzyme for the drug. It inhibits the UDP-glucuronosyltransferases UGT1A1 and UGT1A4. Lenvatinib induces CYP3A but not UGT1A1 and UGT1A4. Use of other drugs, especially ones metabolized by the liver enzyme CYP3A, should be monitored in case their plasma concentration changes. In vitro studies have shown that lenvatinib inhibits organic anion transporters 1 and 3 (OAT1 and OAT3). Sunitinib is metabolized in the liver by CYP3A4. It interacts with inducers and inhibitors of CYP3A4 leading to a decrease or increase in the plasma concentration of particular drugs metabolized by the same pathway. It will not change the amount of drug metabolized by the enzyme, because it does not inhibit or induce the enzyme directly. Sunitinib is a substrate of P-glycoprotein and ABCG2 transporters. It acts as an inhibitor for both transporters, especially for ABCG2. Therefore, drugs that are substrates of these carriers will have modified pharmacokinetics. Plasma concentration of sorafenib and paclitaxel may be increased when the drugs are co-administered along with carboplatin. This has no effect on carboplatin. It also increases the AUC of docetaxel, doxorubicin and irinotecan but decreases the AUC of fluorouracil and neomycin, so it is cautionary to administer sorafenib with these drugs as it may alter the plasma concentration. Sorafenib is metabolized by CYP3A4 and UGT1A9. This means that drugs metabolized by these pathways have to be carefully administered.
In nuclear physics, beta decay (β-decay) is a type of radioactive decay in which an atomic nucleus emits a beta particle (fast energetic electron or positron), transforming into an isobar of that nuclide. For example, beta decay of a neutron transforms it into a proton by the emission of an electron accompanied by an antineutrino; or, conversely a proton is converted into a neutron by the emission of a positron with a neutrino in what is called positron emission. Neither the beta particle nor its associated (anti-)neutrino exist within the nucleus prior to beta decay, but are created in the decay process. By this process, unstable atoms obtain a more stable ratio of protons to neutrons. The probability of a nuclide decaying due to beta and other forms of decay is determined by its nuclear binding energy. The binding energies of all existing nuclides form what is called the nuclear band or valley of stability. For either electron or positron emission to be energetically possible, the energy release or Q value must be positive. Beta decay is a consequence of the weak force, which is characterized by relatively long decay times. Nucleons are composed of up quarks and down quarks, and the weak force allows a quark to change its flavour by means of a virtual W boson leading to creation of an electron/antineutrino or positron/neutrino pair. For example, a neutron, composed of two down quarks and an up quark, decays to a proton composed of a down quark and two up quarks.
Besides platformer gameplay, one of the game's most distinctive gameplay features is allowing to switch the player character's form to suit one's needs. The player begins the game as Maui, whose only means of self-defence is an insect-launching pistol that can launch several forms of bugs, some of them combined for greater effect. However, once the player reaches the second level, Maui transforms into Cold Shadow, his ninja alter ego, who defends himself with short-range attacks using a bo staff. Cold Shadow's staff is also primarily used to explore the level further, such as climbing a narrow tunnel. After the second level, the player can switch back and forth between Maui and Cold Shadow at will, provided he has enough ninja tokens for the transformation. The amount of ninja tokens Maui or Cold Shadow holds determines Cold Shadow's strength – who can then chain more and more attacks as his skill improves – when played as him in the SNES version. On Mega Drive, however, Maui needs to collect red ninja tokens instead, the amount of white tokens being useful for metamorphosis alone. Some levels of the game, however, prevent Maui from transforming at all, as Cold Shadow cannot bungee jump on vines, for example, which forces the player to use Maui throughout the level.
Sources: en.wikipedia.org
=== Therapeutic potential === Excessive IGF-1 activity promotes tumorigenesis while reduced IGF-1 activity is linked with diseases such as Alzheimer's disease and Parkinson's disease. cGP normalises the autocrine function of IGF-1 under pathological conditions and when there are low levels of cGP in the human body, IGF-1 regulation is compromised. Therefore, it is reasonable to assume that treatment with exogenous cGP could assist with improving IGF-1 implicated health benefits.
In 1869 Dmitrii Mendeleev reported that when he arranged the elements in a row according to their atomic weights, there was a certain periodicity to them. For instance, the second element, lithium, had similar properties to the ninth element, sodium, and the sixteenth element, potassium — a period of seven. Likewise, beryllium, magnesium, and calcium were similar and all were seven places apart from each other on Mendeleev's table. Using these patterns, Mendeleev predicted the existence and properties of new elements, which were later discovered in nature: scandium, gallium, and germanium. Moreover, the periodic table could predict how many atoms of other elements that an atom could bond with — e.g., germanium and carbon are in the same group on the table and their atoms both combine with two oxygen atoms each (GeO2 and CO2). Mendeleev found these patterns validated atomic theory because it showed that the elements could be categorized by their atomic weight. Inserting a new element into the middle of a period would break the parallel between that period and the next, and would also violate Dalton's law of multiple proportions.
==== Human rights violations at Abu Ghraib and Haditha ==== Hitchens criticised human rights abuses by US forces in Iraq but argued that conditions had improved considerably compared either to Saddam Hussein's previous regime or to previous US military actions in Vietnam. In 2005, Hitchens criticised the abuse of prisoners in Abu Ghraib but argued that overall "prison conditions at Abu Ghraib have improved markedly and dramatically since the arrival of Coalition troops in Baghdad", arguing that "before March 2003, Abu Ghraib was an abattoir, a torture chamber, and a concentration camp." In a 5 June 2006 article on the alleged killings of Iraqi civilians by U.S. Marines in Haditha, Hitchens argued that whether or not a massacre had taken place, comparisons with the My Lai massacre in Vietnam were "so much propaganda and hot air" that ignored substantial changes in the rules of engagement and US Army procedures and training designed to prevent and discourage such an event. He argued that lesson had been learned such that "as a consequence, a training film about My Lai – "if anything like this happens, you have really, truly screwed up" – has been in use for U. S. soldiers for some time".
Holick helped develop the first clinical assays for 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, determined how vitamin D3 is made in the skin from sun exposure, and established how season, time of day, skin pigmentation, sunscreen use, and latitude influenced this vital cutaneous process. He established that the skin was not only the organ responsible for making vitamin D3 but was also a target tissue for its active form, 1,25-dihydroxyvitamin D3. He determined the extremely inhibitory effects of 1,25-dihydroxyvitamin D3 on keratinocyte proliferation and the promoting effects on differentiation, and translated these seminal observations by demonstrating that the topical application of 1,25-dihydroxyvitamin D3 and several of its analogs were effective for the treatment of psoriasis. He demonstrated that macrophages and prostate cells have the enzymatic machinery to produce 1,25-dihydroxyvitamin D3, and established that the extrarenal production of 1,25-dihydroxyvitamin D3 may play a crucial role not only in cancer prevention but also in regulating the immune system. He developed a vitamin D absorption test and demonstrated that vitamin D was bioavailable in orange juice, leading to fortification of juice products in the United States. He also used the test to demonstrate the major cause of vitamin D deficiency in obesity is sequestration of vitamin D in the fat. He helped perform dose escalation studies establishing how much vitamin D is required to maintain blood levels of 25-hydroxyvitamin D in the sufficient range for adults.
Sources: en.wikipedia.org
=== Regulation in Britain and the United States === Before the 1920s, regulation in Britain was controlled by pharmacists. Pharmacists who were found to have prescribed opium for illegitimate uses and anyone found to have sold opium without proper qualifications would be prosecuted. With the passing of the Rolleston Act in Britain in 1926, doctors were allowed to prescribe opiates such as morphine and heroin if they believed their patients demonstrated a medical need. Because addiction was viewed as a medical problem rather than an indulgence, doctors were permitted to allow patients to wean themselves off opiates rather than cutting off any opiate use altogether. The passing of the Rolleston Act put the control of opium use in the hands of medical doctors instead of pharmacists. Later in the 20th century, addiction to opiates, especially heroin in young people, continued to rise and so the sale and prescription of opiates was limited to doctors in treatment centres. If these doctors were found to be prescribing opiates without just cause, then they could lose their licence to practice or prescribe drugs. Abuse of opium in the United States began in the late 19th century and was largely associated with Chinese immigrants. During this time the use of opium had little stigma; the drug was used freely until 1882 when a law was passed to confine opium smoking to specific dens. Until the full ban on opium-based products came into effect just after the beginning of the twentieth century, physicians in the US considered opium a miracle drug that could help with many ailments.
== History == Dantrolene was first described in the scientific literature in 1967, as one of several hydantoin derivatives proposed as a new class of muscle relaxant. Dantrolene underwent extensive further development, and its action on skeletal muscle was described in detail in 1973. Dantrolene was widely used in the management of spasticity before its efficacy in treating malignant hyperthermia was discovered by South African anesthesiologist Gaisford Harrison and reported in a landmark 1975 article published in the British Journal of Anaesthesia. Harrison experimentally induced malignant hyperthermia with halothane anesthesia in genetically susceptible pigs, and obtained an 87.5% survival rate, where seven of his eight experiments survived after intravenous administration of dantrolene. The efficacy of dantrolene in humans was later confirmed in a large, multicenter study published in 1982, and confirmed epidemiologically in 1993. Before dantrolene, the only available treatment for malignant hyperthermia was either procainamide or procaine, the latter being associated with a 60% mortality rate in animal models.
1-Aminocyclopropane-1-carboxylic acid (ACC) is a disubstituted cyclic α-amino acid in which a cyclopropane ring is fused to the Cα atom of the amino acid. It is a white solid. Many cyclopropane-substituted amino acids are known, but this one occurs naturally in various fruits. Like glycine, but unlike most α-amino acids, ACC is not chiral.
== Biosynthesis, synthesis, and reactivity == Patulin is biosynthesized from 6-methylsalicylic acid via multiple chemical transformations. Isoepoxydon dehydrogenase (IDH) is an important enzyme in the multi-step biosynthesis of patulin. Its gene is present in other fungi that may potentially produce the toxin. It is reactive with sulfur dioxide, so antioxidant and antimicrobial agents may be useful to destroy it. Levels of nitrogen, manganese, and pH as well as abundance of necessary enzymes regulate the biosynthetic pathway of patulin.
Alternative methods of preservation, such as ice packing or laying the body on so called 'cooling boards', gradually lost ground to the increasingly popular and effective methods of embalming. By the mid-19th century, the newly emerging profession of businessmen-undertakers – who provided funeral and burial services – began adopting embalming methods as standard. Embalming became more common in the United States during the American Civil War, when servicemen often died far from home. The wish of families for their remains to be returned home for local burial and lengthy transport from the battlefield helped it become popular. The period from about 1861 is sometimes known as the funeral period of embalming and is marked by a separation of the fields of embalming by undertakers and embalming (anatomical wetting) for medical and scientific purposes. Dr Thomas Holmes received a commission from the Army Medical Corps to embalm the corpses of dead Union officers to return to their families. Military authorities also permitted private embalmers to work in military-controlled areas. The passage of Abraham Lincoln's body home for burial was made possible by embalming, and it brought wider public attention to the possibilities and potential of embalming. Until the early 20th century, embalming fluids often contained arsenic until it was supplanted by more effective and less toxic chemicals.
Sources: en.wikipedia.org
特沙莫瑞林是国际éžä¸“利å称，指一ç§ç»è¿‡ N ç«¯ä¿®é¥°çš„ç”Ÿé•¿æ¿€ç´ é‡Šæ”¾æ¿€ç´ ç±»ä¼¼ç‰©ã€‚å®ƒè¢«å½’ç±»ä¸ºåˆæˆè‚½ï¼Œåºåˆ—与 GHRH(1-44) 密切相关。该å称ä¸æŒ‡ä»£ä»»ä½•ç‰¹å®šå“牌或剂型。
监管批准集ä¸äºŽ HIV 感染相关的脂肪è¥å…»ä¸è‰¯ï¼Œç›®çš„是å‡å°‘内è„脂肪。它未被批准用于普通肥胖或一般体é‡ç®¡ç†ã€‚ä¸åŒå›½å®¶çš„批准状æ€å’Œæ ‡ç¾èŒƒå›´å¯èƒ½ä¸åŒã€‚
长期心血管获益ã€æ»äº¡çŽ‡å½±å“以åŠåœè¯åŽçš„æŒç»æ€§ä»ç¼ºä¹ç¡®è¯ã€‚éƒ¨åˆ†ç ”ç©¶æ示 IGF-1 和血糖å‚æ•°å¯èƒ½å˜åŒ–，但个体差异较大。这些开放问题需è¦æ›´é•¿æœŸã€æ›´å¤§è§„模的试验æ¥å›žç”。
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.